Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hip fracture

Denosumab Dosing Delays Tied to Increased Fracture Risk

Megan Brooks  |  July 27, 2020

NEW YORK (Reuters Health)—Denosumab injection delays of more than four months are associated with an increased risk of fracture compared with on-time injections, especially at the spine, new research indicates. “This study suggests the importance of timely denosumab administration when used for long-term osteoporosis management,” the researchers write in Annals of Internal Medicine.1 “When starting…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:denosumabfracture riskFracturesOsteoporosisosteoporosis treatments

Bone Density Concerns: Guidance on Tackling Fracture Risk in CKD

Thomas R. Collins  |  July 7, 2020

Suggestions on how to assess risk and manage bone issues in chronic kidney disease patients are offered…

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)chronic kidney diseaseEULARfracture riskFractureskidneyOsteoporosisosteoporosis treatments

If It’s Broken, Fix It: Can an Automated System Predict Short-Term Fracture Risk?

Jason Liebowitz, MD, FACR  |  September 17, 2019

A clinician’s ability to determine which patients are at greatest risk for hip or other fracture is improving with the use of algorithm-based fracture risk calculators…

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:EULARfracture riskfracture risk evaluation modelFracturesOsteoporosisTechnology

Prevent Osteoporotic Fractures with a Fracture Liaison Service

Micah Yu, MD, Anna Lafian, DO, & Christina Downey, MD  |  May 18, 2019

Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with osteoporosis and fractures…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:FracturesOsteoporosisosteoporosis treatmentsosteoporotic fracture rates

Osteoporotic Fracture Rates Similar with Denosumab, Alendronate in Real World

Megan Brooks  |  April 25, 2019

NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:alendronatedenosumabFracturesOsteoporosisosteoporosis treatmentsosteoporotic fracture rates

Insights on the Diagnosis & Treatment of Low Back & Hip Pain

Susan Bernstein  |  March 19, 2019

CHICAGO—Two experts presented insights on the diagnosis and treatment of low back and hip pain, including a refresher course on the mechanical structures involved, in Anatomy in a Day: Demystifying Low Back Pain and Lateral Hip Pain: New Patho-Anatomical Perspectives, a session at the 2018 ACR/ARHP Annual Meeting. Low Back Pain Avoid using such terms…

Filed under:ConditionsMeeting Reports Tagged with:2018 ACR/ARHP Annual Meetinghip painlow back painUltrasound

Bone Mineral Density Most Important Determinant of Fracture Risk

Reuters Staff  |  September 7, 2018

NEW YORK (Reuters Health)—In what is believed to be the largest study investigating genetic and clinical determinants of osteoporotic fracture risk, only a genetic predisposition to low bone mineral density (BMD) had a potential causal role to play. “Notably, genetic predisposition to lower levels of vitamin D and estimated calcium intake from dairy sources were…

Filed under:ConditionsOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:bone mineral density (BMD)fracture riskfracture risk determinantFracturesOsteoporosis

Hip Bone Deterioration May Differ Significantly Between Men & Women

Marilynn Larkin  |  June 12, 2018

NEW YORK (Reuters Health)—Various image analysis techniques show sex-specific patterns of bone deterioration at the hip, suggesting that men and women should be assessed differently for hip fracture risk, researchers say. “One major contribution of this work is the integration of data-driven computational anatomy approaches, which showed that proximal femur fragility linked to fracture seems…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:bone mineral density (BMD)Fractureship fracturehip fracture riskOsteoporosisSex Differences

Higher Fracture Risk in Patients with Polymyalgia Rheumatica, Giant-Cell Arteritis

Will Boggs MD  |  January 24, 2018

NEW YORK (Reuters Health)—Patients with polymyalgia rheumatica (PMR) and giant-cell arteritis (GCA) have similarly increased risks of fracture, compared with the general population, researchers have found. “It is of surprise that patients with GCA have a similar fracture risk to those with PMR,” Dr. Zoe Paskins from Keele University, in Staffordshire, told Reuters Health by…

Filed under:ConditionsVasculitis Tagged with:fracture riskFracturesgiant cell arteritis (GCA)Polymyalgia Rheumatica

Changes in Bone Markers Predict Fracture Reduction with Anti-Resorptive Drug

Will Boggs MD  |  January 17, 2018

NEW YORK (Reuters Health)—Treatment-related changes in bone formation markers predict vertebral-fracture reduction with anti-resorptive drug therapy, according to a meta-regression analysis of 14 clinical trials. “These results may be useful for the development of new osteoporosis treatments or when considering new populations or dosing regimens with existing treatments,” Dr. Douglas C. Bauer from the University…

Filed under:ConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:anti-resorptive drug therapybone marker changesfracture reductionFracturesOsteoporosisosteoporosis treatments

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 27
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences